These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26510815)

  • 21. Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation.
    Scomparin A; Polyak D; Krivitsky A; Satchi-Fainaro R
    Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1294-309. PubMed ID: 25916823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TIDES 2006--IBC conference. Oligonucleotide and peptide technology and product development. 1-3 May 2006, Carlsbad, CA, USA.
    Hartmann G
    IDrugs; 2006 Jul; 9(7):460-3. PubMed ID: 16821153
    [No Abstract]   [Full Text] [Related]  

  • 23. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The delivery of therapeutic oligonucleotides.
    Juliano RL
    Nucleic Acids Res; 2016 Aug; 44(14):6518-48. PubMed ID: 27084936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule oligonucleotides as smart modality for antiviral therapy: a medicinal chemistry perspective.
    Kar SS; Dhar AK; Palei NN; Bhatt S
    Future Med Chem; 2023 Jun; 15(12):1091-1110. PubMed ID: 37584172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in oligonucleotide drug delivery.
    Roberts TC; Langer R; Wood MJA
    Nat Rev Drug Discov; 2020 Oct; 19(10):673-694. PubMed ID: 32782413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug delivery of oligonucleotides by peptides.
    Lochmann D; Jauk E; Zimmer A
    Eur J Pharm Biopharm; 2004 Sep; 58(2):237-51. PubMed ID: 15296952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
    Uhlmann E
    Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
    Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanotechnology and aptamers: applications in drug delivery.
    Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
    Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Water-soluble, meso-substituted cationic porphyrins--a family of compounds for cellular delivery of oligonucleotides.
    Flynn SM; George ST; White L; Devonish W; Takle GB
    Biotechniques; 1999 Apr; 26(4):736-42, 744, 746. PubMed ID: 10343913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting.
    Scheicher B; Schachner-Nedherer AL; Zimmer A
    Eur J Pharm Sci; 2015 Jul; 75():54-9. PubMed ID: 25896372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic RNA-silencing oligonucleotides in metabolic diseases.
    Goga A; Stoffel M
    Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oligonucleotide delivery in cancer therapy.
    De Rosa G; De Stefano D; Galeone A
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1263-78. PubMed ID: 20977291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study toward practical use of oligonucleotide therapeutics].
    Inoue T; Yoshida T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for designing clinical trials for oligonucleotide therapeutics.
    Wacheck V
    Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic oligonucleotides and delivery technologies: Research topics in Japan.
    Murakami M
    Drug Discov Ther; 2016; 10(5):234-235. PubMed ID: 27890898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.
    Campbell MA; Wengel J
    Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oligonucleotide pharmacotherapy: an antigene strategy.
    Nagel KM; Holstad SG; Isenberg KE
    Pharmacotherapy; 1993; 13(3):177-88. PubMed ID: 8321732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.